Soluble E-cadherin as a Marker for Gastric Cancer
Author Information
Author(s): J Gofuku, H Shiozaki, Y Doki, M Inoue, M Hirao, N Fukuchi, M Monden
Primary Institution: Osaka University Medical School
Hypothesis
Can serum soluble E-cadherin (S-ECD) serve as a reliable tumor marker for gastric cancer?
Conclusion
Serum S-ECD levels are significantly higher in gastric cancer patients compared to healthy individuals, suggesting its potential as a tumor marker.
Supporting Evidence
- Serum S-ECD levels were significantly higher in gastric cancer patients (4735 ± 2310 ng/ml) than in healthy volunteers (2515 ± 744 ng/ml).
- 67% of gastric cancer patients showed abnormally high serum S-ECD levels, which is significantly higher than other tumor markers like CEA and CA19-9.
- Post-operative serum S-ECD levels decreased significantly after surgical removal of tumors.
Takeaway
Doctors found that a protein called soluble E-cadherin is much higher in the blood of people with stomach cancer than in healthy people, which could help in diagnosing the disease.
Methodology
Serum S-ECD levels were measured using a sandwich-type enzyme immunoassay kit, and E-cadherin expression was evaluated through immunohistochemistry.
Limitations
There was no significant correlation between serum S-ECD levels and clinicopathological factors such as tumor invasion or metastasis.
Participant Demographics
The study included 81 gastric cancer patients (60 men and 21 women) with a mean age of 63 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website